Novartis Gives Up On Rituxan Biosimilar For US Market

 
• By Kevin Grogan and Alexandra Shimmings
  
Boxing
Novartis calls it quits on Rituxan biosimilar • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas